Home|Journals|Articles by Year|Audio Abstracts
 

Mini Review



COVID-19 drugs: A necessary strategy for living with COVID-19 in the new normal and the mutations of the SARS-CoV-2 such as omicron variant

Dinh-Toi chu, Nhat Le Bui, Yen-Vy Nguyen Thi, Suong-Mai Vu Ngoc.




Abstract

The COVID-19 pandemic has spread rapidly and caused significant damage to global public health as well as the economy. While the race of vaccine development witnessed a spectacular breakthrough with the introduction of highly effective vaccines such as BNT162b2, mRNA-1273, or AZD1222, no specific drug for COVID-19 treatment has been discovered yet. Recently, repurposing drugs classified into three main groups of mechanisms, including antivirus, anti-SARS-CoV-2 antibodies, and immunomodulators, are investigated. As a result, Remdesivir and six other drugs are authorized by the Food and Drug Administration (FDA) to treat patients infected by the SARS-CoV-2. This work aims to highlight that, besides vaccines, COVID-19 drugs should get more attention and be considered as one of the most promising strategies to safely coexist with the SARS-CoV-2 virus in the new normal status and for the mutations of the virus, such as the omicron variant.

Key words: Covid-19 drugs; Strategy; Covid-19; the new normal; mutation of the Sar-CoV2 virus; omicron variant






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.